M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy
L Zhao,Y Zhang,F Liu,H Yang,Y Zhong,Y Wang,S Li,Q Su,L Tang,L Bai,H Ren,Y Zou,S Wang,S Zheng,H Xu,L Li,J Zhang,Z Chai,Mark E. Cooper,N Tong +19 more
TL;DR: Urinary abundance of complement proteins was significantly associated with ESRD in patients with T2DM and biopsy-proven DN, indicating that therapeutically targeting the complement pathway may alleviate progression of DN.
Journal ArticleDOI
SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
TL;DR: SGLT2 inhibitors have the potential to transform the clinical care of persons with T2DM by not only improving glycaemic control but also reducing blood pressure, body weight and diabetes-related end-organ complications.
Journal ArticleDOI
A regional soil and river sediment geochemical study in Baoshan area, Yunnan province, southwest China
Li Zhang,Jennifer McKinley,Mark E. Cooper,Min Peng,Min Peng,Qiaolin Wang,Yuntao Song,Hangxin Cheng +7 more
TL;DR: In this paper, the concentration and distribution of selected chemical elements in surface environments and the influence of natural factors (geological background, geomorphology) and anthropogenic factors (mining activities, land-use, agricultural fertilization) on their distribution in the Baoshan area, Yunnan province, southwest China.
Journal ArticleDOI
Synthesis of octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria.
Bernd Becker,Mark S. Butler,Karl A. Hansford,Alejandra Gallardo-Godoy,Alysha G. Elliott,Johnny X. Huang,David Edwards,Mark A. T. Blaskovich,Mark E. Cooper +8 more
TL;DR: The first synthesis of octapeptin C4 was achieved using a combination of solid phase synthesis and off-resin cyclisation, which displayed antibiotic activity against multi-drug resistant, NDM-1 and polymyxin-resistant Gram-negative bacteria.